© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma
Investigators Present Updated Results of the OpACIN Trial for Melanoma
July 21, 2020
Christian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.
Pembrolizumab Shows Long-Term Benefit in Advanced Melanoma Subgroups
July 17, 2020
A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.
Novel PKC Inhibitor Trial to Expand Its Cohort of Patients With Solid Tumors
July 17, 2020
The phase 2 basket arm trial of IDE196 in patients with solid tumors harboring GNAQ or GNA11 hotspot mutations has met its clinical protocol criteria for cohort expansion.
Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure
June 27, 2020
In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.
Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
June 23, 2020
Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Fast Track Designation Granted to Seviprotimut-L Vaccine for Adjuvant Use in Stage IIB/IIC Melanoma
June 23, 2020
With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,
3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma
June 18, 2020
Alexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.
Prior ICI Associated With Longer PFS in BRAF V600E+ Melanoma Treated With Dabrafenib and Trametinib
June 04, 2020
"..These findings may be susceptible to selection bias since patients with more aggressive disease may be more likely to start dabrafenib and trametinib in the first line."
Autologous Tumor-Infiltrating Lymphocytes Effective for Treatment of Metastatic Melanoma
June 01, 2020
"We are very pleased to announce our pivotal cohort 4 early data from the C-144-01 clinical study in advanced melanoma today."
Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma
May 30, 2020
Encorafenib plus binimetinib show sustained overall survival and progression-free survival benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS study.